Related Experiment Video
Updated: May 22, 2026
11:29
Anteromesial Temporal Lobectomy for Medically Intractable Temporal Lobe Epilepsy: An Operative Study
Published on: August 15, 2025
Topiramate and temporal lobe epilepsy: an open-label study
Angelo Labate1, Antonio Siniscalchi, Laura Mumoli
1Institute of Neurology, University Magna Græcia, Catanzaro, Italy. labate@unicz.it
Summary
Topiramate (TPM) effectively reduced seizures in temporal lobe epilepsy (TLE) patients. This observational study found TPM well-tolerated, particularly in mild TLE cases, with many achieving seizure freedom or significant reduction.
Area of Science:
- Neurology
- Clinical Pharmacology
Background:
- Temporal lobe epilepsy (TLE) is a common focal epilepsy.
- Effective antiepileptic drug (AED) management is crucial for TLE patients.
- Topiramate (TPM) is an established AED with broad-spectrum activity.
Purpose of the Study:
- To assess the efficacy and tolerability of topiramate (TPM) as monotherapy for temporal lobe epileptic seizures.
- Evaluate TPM's effectiveness in reducing seizure frequency in TLE patients.
- Determine TPM's safety profile and tolerability in an observational setting.
Main Methods:
- Observational study of 41 TLE patients (mean age 54±18 years).
- Patients received TPM (50-600 mg/day) as monotherapy or add-on therapy.
- Seizure frequency and adverse events were monitored over a minimum two-year follow-up.
Main Results:
- 28 out of 41 patients achieved complete seizure freedom.
- 10 patients experienced a ≥ 50% reduction in seizure frequency.
- Only one patient discontinued TPM due to adverse effects, with two showing poor response.
Conclusions:
- Topiramate (TPM) is effective in reducing seizure frequency for TLE patients, whether used as monotherapy or add-on.
- TPM demonstrates high efficacy and excellent tolerability, especially in patients with mild TLE.
- The findings support TPM's role in managing TLE across various treatment scenarios.
Related Concept Videos
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:24Epilepsy and Seizures: Overview
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:20Seizures l: Introduction
Understanding seizures and epilepsy relies on key definitions that help in recognizing, classifying, and managing these disorders. These definitions provide a framework for recognizing, classifying, and managing seizure disorders.DefinitionsA seizure is a sudden, abnormal burst of electrical activity in the brain that can cause changes in awareness, movement, sensation, or behavior, depending on the area involved. Epilepsy is a chronic condition characterized by recurrent, unprovoked seizures,...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:14Antiepileptic Drugs: Glutamate Antagonists
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...